TELA Bio ( (TELA) ) just unveiled an announcement.
TELA Bio, Inc. has disclosed preliminary financial results for Q3 2024, showing an estimated revenue increase to $19.0 million from $15.1 million in the same period of 2023, with a gross margin slightly decreasing to 68%. The company ended the quarter with $17.3 million in cash, down from $46.7 million at the end of 2023. These results are unaudited and subject to revisions, urging investors to interpret the data cautiously.
See more insights into TELA stock on TipRanks’ Stock Analysis page.
